Exemestane vs HGH
FDA Approved vs FDA Approved
synergistic Mechanism-based · 70% HGH helps manage estrogen conversion from Exemestane. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
Exemestane HGH
Weight 296.40 Da 22,124 Da
Half-life ~24 hours 3-4 hours (SC), 20-30 minutes (IV)
Chain — 191 amino acids
Type Steroidal aromatase inhibitor (irreversible, suicide inhibitor) Single-chain polypeptide with two disulfide bridges
Key Benefits
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Dosing Protocols
Exemestane
12.5mg EOD or 25mg E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Side Effects
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Contraindications
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Research Evidence
Exemestane HGH
Status FDA Approved FDA Approved
References 5 studies 4 studies
Latest — 2024
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.